UK Markets closed

Vifor Pharma AG (GNHAY)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
28.360.00 (0.00%)
At close: 3:35PM EDT
Full screen
Loading interactive chart…
  • Abbas Hussain Appointed as New Chief Executive Officer of Vifor Pharma
    Business Wire

    Abbas Hussain Appointed as New Chief Executive Officer of Vifor Pharma

    ST. GALLEN, Switzerland, June 24, 2021--Regulatory News: Abbas Hussain (56, British citizen) has a successful and international career of more than 30 years as an executive in the healthcare sector. From 2008 to 2017, Abbas Hussain held various leadership positions for the British pharmaceutical group GlaxoSmithKline, most recently as Global President Pharmaceuticals and Vaccines for five years. Prior to that, he worked for 20 years for the U.S. pharmaceutical group Eli Lilly, holding management

  • Vifor Pharma to revise DIAMOND study, readout expected in H2 2021
    Business Wire

    Vifor Pharma to revise DIAMOND study, readout expected in H2 2021

    ST. GALLEN, Switzerland, June 24, 2021--Regulatory News: Vifor Pharma Group today announced that the phase-IIIb DIAMOND study has been amended with new and clinically relevant endpoints, including a new primary endpoint of efficacy in potassium management in high-risk heart failure patients treated with guideline-recommended doses of renin-angiotensin aldosterone system inhibitor (RAASi). This decision has been made on the recommendation from the independent study Executive Committee and followi

  • Vifor Pharma and Cara Therapeutics announce U.S. FDA acceptance and Priority Review of NDA for KORSUVA™* injection in hemodialysis patients with moderate-to-severe pruritus
    Business Wire

    Vifor Pharma and Cara Therapeutics announce U.S. FDA acceptance and Priority Review of NDA for KORSUVA™* injection in hemodialysis patients with moderate-to-severe pruritus

    Regulatory News: Vifor Pharma and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the New Drug Application (NDA) for KORSUVA™ (difelikefalin) solution for injection for the treatment of moderate-to-severe pruritus in hemodialysis patients.